![Normand Balthazard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Normand Balthazard
Corporate Officer/Principal bei
Origenix Technologies, Inc.
Profil
Normand Balthazard is the founder of CryoCath Technologies, Inc., ConjuChem, Inc., Biorthex, Inc., Intellivax International, Inc., Origenix Technologies, Inc. Former positions include President & Chief Executive Officer at BioCapital Investment Advisors, Inc. from 2002 to 2005, Co-Chief Executive Officer at Prognomix, Inc., Chairman, President, Secretary & Treasurer at Contact Image Corp.
from 2004 to 2007, and Director at Savaria Corp.
from 2003 to 2010.
Aktive Positionen von Normand Balthazard
| Unternehmen | Position | Beginn |
|---|---|---|
Origenix Technologies, Inc. | Corporate Officer/Principal | - |
Intellivax International, Inc.
 Intellivax International, Inc. Pharmaceuticals: MajorHealth Technology Develops nasal spray vaccines | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Normand Balthazard
| Unternehmen | Position | Ende |
|---|---|---|
Prognomix, Inc.
 Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications | Vorstandsvorsitzender | 01.10.2012 |
| SAVARIA CORPORATION | Direktor/Vorstandsmitglied | 01.03.2010 |
Contact Image Corp.
 Contact Image Corp. Commercial Printing/FormsCommercial Services Provides digital and fabric printing services | Vorsitzender | 23.03.2007 |
BioCapital Investment Advisors, Inc.
 BioCapital Investment Advisors, Inc. Investment ManagersFinance The fundamental investment objective of BioCapital is to provide investors superior capital appreciation by investing in equity securities of public companies with high growth potential in biotechnology industries. They seek to achieve this fundamental objective by investing in a diversified portfolio of public companies primarily in the following sectors of the biotechnology industry: therapeutics in the fields of cancer, cardiology, infectious diseases, immune system and central nervous system. The firm also invests in companies developing platform technologies in the fields on genomics and proteomics, drug delivery, theranostics, nanotechnology and monoclonal antibody. | Präsident | 31.12.2005 |
Biorthex, Inc.
 Biorthex, Inc. Medical SpecialtiesHealth Technology Designs, develops, manufactures and markets surgical products | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
13
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
CryoCath Technologies, Inc.
 CryoCath Technologies, Inc. Medical SpecialtiesHealth Technology Manufactures medical equipment | Health Technology |
ConjuChem, Inc.
 ConjuChem, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs or pharmaceutical substances to treat Type 2 diabetes or other diagnostic substances | Health Technology |
Savaria Corp.
 Savaria Corp. Other Consumer SpecialtiesConsumer Durables Designs and manufactures elevators, lifts and wheelchair accessible vans | Consumer Durables |
Biorthex, Inc.
Biorthex, Inc. Medical SpecialtiesHealth Technology Designs, develops, manufactures and markets surgical products | Health Technology |
BioCapital Investment Advisors, Inc.
BioCapital Investment Advisors, Inc. Investment ManagersFinance The fundamental investment objective of BioCapital is to provide investors superior capital appreciation by investing in equity securities of public companies with high growth potential in biotechnology industries. They seek to achieve this fundamental objective by investing in a diversified portfolio of public companies primarily in the following sectors of the biotechnology industry: therapeutics in the fields of cancer, cardiology, infectious diseases, immune system and central nervous system. The firm also invests in companies developing platform technologies in the fields on genomics and proteomics, drug delivery, theranostics, nanotechnology and monoclonal antibody. | Finance |
Intellivax International, Inc.
Intellivax International, Inc. Pharmaceuticals: MajorHealth Technology Develops nasal spray vaccines | Health Technology |
Contact Image Corp.
Contact Image Corp. Commercial Printing/FormsCommercial Services Provides digital and fabric printing services | Commercial Services |
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications | Health Technology |
Origenix Technologies, Inc. |
